Comparative Pharmacology
Head-to-head clinical analysis: NIMBEX versus PAVULON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIMBEX versus PAVULON.
NIMBEX vs PAVULON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, blocking neurotransmission and inducing muscle relaxation.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, blocking transmission of nerve impulses to skeletal muscle.
0.15-0.2 mg/kg IV bolus for intubation; maintenance infusion 1-2 mcg/kg/min (initial) adjusted to effect.
0.04-0.1 mg/kg IV bolus for intubation; maintenance: 0.01-0.015 mg/kg IV every 25-60 minutes as needed or continuous IV infusion: 1-2 mcg/kg/min.
None Documented
None Documented
Terminal elimination half-life approximately 20-30 minutes in healthy adults; prolonged in hepatic or renal impairment.
Terminal elimination half-life 100-120 minutes in adults with normal renal function; prolonged in renal impairment.
Primarily renal (80% as unchanged drug and metabolites); biliary/fecal excretion accounts for <20%.
Renal 80-100% as unchanged drug and metabolites; biliary/fecal negligible (<5%).
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent